LUTS: Lower Urinary Tract Symptoms最新文献

{"title":"The Effect of Providing Video-Animated Information to Female Patients With Stress Urinary Incontinence Before the Urodynamic Study on the Patient's Anxiety, Pain, Satisfaction, and Willingness to Repeat the Procedure","authors":"Recep Burak Degirmentepe,&nbsp;Muammer Bozkurt,&nbsp;Eyyup Danis,&nbsp;Deniz Gul,&nbsp;Yasir Muhammed Akca,&nbsp;Haci Ibrahim Cimen,&nbsp;Fikret Halis","doi":"10.1111/luts.70007","DOIUrl":"10.1111/luts.70007","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To investigate the effect of providing video-animated information to female patients with stress urinary incontinence before urodynamics on the patient's anxiety, pain, satisfaction, and willingness to repeat the procedure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Before the procedure, patients were divided into two groups with 1:1 randomization. While one group was given written and verbal information, the other group was additionally given animated video information accompanied by a doctor. Pre-procedure anxiety, hemodynamic parameters during the procedure, as well as post-procedure pain, satisfaction and willingness to repeat the procedure were compared between the groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>STAI-s levels were found to be statistically significantly lower in the group given video animation information before urodynamics (<i>p</i> &lt; 0.01). It was observed that video information had a positive effect on systolic blood pressure, diastolic blood pressure and heart rate, and the values were measured lower compared to the other group (<i>p</i> &lt; 0.01). While there was no statistically significant difference between the two groups in VAS-pain scores (<i>p</i> = 0.82), VAS-satisfaction and VAS-willingness to repeat the procedure scores were found to be statistically significantly different (<i>p</i> &lt; 0.01). It was observed that video-animated information made a positive contribution to satisfaction and willingness to repeat the procedure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Video-animated information given to female patients before urodynamics has positive effects on the patient's anxiety. It also contributes positively to the patient's satisfaction and their willingness to repeat the procedure. Video-animated information may be used routinely in addition to written and verbal information before urodynamics.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of Mesh Reinforcement in Pubic Fixation Urethral Sling Surgery for Urinary Incontinence After Radical Prostatectomy","authors":"Yasutomo Suzuki,&nbsp;Naoto Hodotsuka,&nbsp;Eigo Kuribayashi,&nbsp;Kyota Suzuki,&nbsp;Yuichiro Honda,&nbsp;Shuma Endo,&nbsp;Yukihiro Kondo","doi":"10.1111/luts.70003","DOIUrl":"10.1111/luts.70003","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>In our institution, a unique sling technique is performed for urinary incontinence after radical prostatectomy. However, in cases of severe urinary incontinence or in the medium to long term, the therapeutic effect may be insufficient. Therefore, a urethral sling technique that provides stronger compression of the bulbar urethra was developed, and its effectiveness was compared with the conventional technique.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Seventeen cases of conventional sling surgery and 16 cases of improved sling surgery were included. The number of pads used per day, safety pad rate, and International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) were evaluated before and after surgery, and a retrospective comparison was made between the two groups. Furthermore, patients were divided into those who used ≤ 4 pads per day before surgery and those who used ≥ 5 pads per day, and the difference between the two groups was examined. We also examined changes over time between groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared with the conventional group, the improved group showed significant improvement in the number of pads per day, safety pad rate, and ICIQ-SF 18 months after surgery. In the group with ≤ 4 preoperative pads, the improved group showed significant improvement in all safety pad rates except at 1 and 12 months after surgery. There were no significant differences in all items between the two groups when the number of preoperative pads was ≥ 5.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The improved urethral sling technique appeared to contribute to improving moderate urinary incontinence by adding a simple procedure, especially for patients using ≤ 4 pads per day.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11750314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Elevated Postvoid Residual Urine Volume Following OnabotulinumtoxinA Treatment for Overactive Bladder: A Pilot Study","authors":"Israel Franco,&nbsp;Marc Schwartz,&nbsp;Kevin Cline,&nbsp;David Glazier,&nbsp;Anand Patel","doi":"10.1111/luts.70004","DOIUrl":"10.1111/luts.70004","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate possible predictors of elevated postvoid residual volume (PVR) following onabotulinumtoxinA administration in patients with idiopathic overactive bladder (OAB), a condition that may include urinary urgency, frequency, and nocturia, without any identifiable cause or underlying neurological or metabolic condition.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Adults who had been treated with 100–200 U onabotulinumtoxinA for OAB and had previous failure of other OAB treatments were identified by retrospective review of medical chart data from three urology clinics in the United States treating patients with a variety of urological conditions. A total of 211 patients were allocated to cohorts based on posttreatment PVR &lt; 200 mL (<i>n</i> = 173) and ≥ 200 mL (<i>n</i> = 38). Logistic regression analyses were performed to evaluate potential predictors of posttreatment PVR ≥ 200 mL, including pretreatment peak urine flow rate (Qmax), average urine flow rate (Qavg), and Modified Liverpool Qmax and Qavg flow index (FI), and to determine whether patient age and baseline PVR were associated with the likelihood of PVR ≥ 200 mL. Patients were excluded if symptoms of OAB were secondary to a neurological condition, they had a PVR &gt; 200 mL within 2 weeks prior to the index therapy or had been treated with other botulinum toxin formulations for a urinary condition.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the predictor analyses, neither Qmax nor Qavg alone was a likely predictor. Odds ratios of PVR ≥ 200 mL for Modified Liverpool Qmax FI and Qavg were 0.30 (95% CI: 0.08–0.91; <i>p</i> = 0.0488) and 0.07 (95% CI 0.01–0.40; <i>p</i> = 0.0045), respectively. When patient age and baseline PVR were incorporated into the analyses, results suggested that Qmax, Qavg, Qmax FI, and Qavg FI, as well as increased age and baseline PVR, were likely predictors of elevated posttreatment PVR.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patients who are older, have high pretreatment PVR values, and have lower pretreatment urine flow indexes and flows may be at increased risk of developing elevated PVR after receiving onabotulinumtoxinA treatment for OAB.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laser-Driven Dissection Achieves Earlier Continence Recovery Than Blunt Dissection During Holmium Laser Enucleation of the Prostate","authors":"Ahmed M. Harraz,&nbsp;Saad Aldousari,&nbsp;Abdelrahman I. Eltafahny,&nbsp;Ali Almoumen,&nbsp;Awad Thahir,&nbsp;Feras Ajrawi,&nbsp;Abdullah Alarbid,&nbsp;Ahmad Alghurair,&nbsp;Mohammad Alghanem,&nbsp;Faisal Alhajeri","doi":"10.1111/luts.70006","DOIUrl":"10.1111/luts.70006","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>During holmium laser enucleation of the prostate (HOLEP), blunt dissection (BD) by pushing the tip of the scope may exert mechanical force on the sphincter that could be avoided by adopting laser dissection (LD). This study evaluates the continence recovery in consecutive patients who underwent BD and LD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A prospective cohort of patients who underwent LD was compared with a retrospective control that underwent BD. In both groups, early apical release was performed, and the adenoma was split at 12 O'clock after complete enucleation. In LD, a trans-capsular plane was sharply created by LD and is guided by the circular capsular fibers. A mechanical push with the resectoscope tip was used to create and maintain the ideal surgical plane in the BD group while the laser energy was used to achieve timely hemostasis. The primary outcome was stress urinary incontinence (SUI), defined as the need to use any number of pads, immediately after catheter removal, at 1 week and 1 month postoperatively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Consecutive 51 (48.6%) and 54 (51.4%) patients underwent BD and LD, respectively. The LD group tends to be older while other demographics were comparable. Both groups were comparable regarding the estimated prostate volume, enucleation time, and postoperative resolution of symptoms. Continence recovery was in favor of the LD group immediately after removing the catheter (77.8% vs. 43.1%; <i>p</i> &lt; 0.001), at 1 week (92.6% vs. 66.7%; <i>p</i> = 0.002), with no significant difference at 1 month (98.1% vs. 88.2%; <i>p</i> = 0.06).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>LD tends to have favorable early continence recovery compared with BD mostly because of less mechanical stress. Minimizing the periods of blunt pushes during the enucleation might benefit continence recovery.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Autologous Fascial Pubovaginal Sling for Recurrent Stress Incontinence: A Retrospective Study","authors":"Jin-Yang Luo,&nbsp;Si-Hong Shen,&nbsp;Zhen-Yang Ye,&nbsp;Li-Jing Xu,&nbsp;Jia-Wei Chen,&nbsp;Liao Peng,&nbsp;Hong Shen,&nbsp;De-Yi Luo","doi":"10.1111/luts.70000","DOIUrl":"10.1111/luts.70000","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This study aimed to analyze the clinical efficacy and safety of autologous fascial pubovaginal sling (AFPVS) surgery in treating recurrent stress urinary incontinence (SUI) following the failure of mid-urethral sling procedures.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective analysis was conducted on the clinical data of SUI patients who underwent AFPVS at our hospital between 2008 June and 2024 June following the failure of mid-urethral sling procedures. The analysis included basic information, surgical parameters, and postoperative complications. Additionally, telephone interviews using the International Consultation on Incontinence Questionnaire-Short Form (ICI-Q-SF) and the Incontinence Quality of Life Questionnaire (I-QOL) was conducted at 6-month follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty-four patients with the mean age of 54.8 ± 15.7 years old were reviewed, and the median disease duration was 3 (2–10) years. Of the 34 patients, 20 (58.8%) were cured, 8 (23.5%) showed improvement, resulting in an overall effectiveness rate of 82.3%. Three cases experienced bladder injury, which resolved after 2 weeks of catheterization, but no patients had urethral or vaginal injuries intraoperatively. Postoperative scores on the ICI-Q-SF significantly decreased (<i>p</i> &lt; 0.001), and postoperative I-QOL scores significantly increased (<i>p</i> &lt; 0.001) compared to preoperative scores.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>AFPVS is a safe and effective salvage procedure for recurrent SUI following the failure of mid-urethral sling procedures.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Silodosin for the Treatment of Female LUTS: A 12-Week Prospective, Single-Center Study","authors":"Chung Beum Wee,&nbsp;Tae-Hyoung Kim,&nbsp;Jong Hyun Tae,&nbsp;Se Young Choi","doi":"10.1111/luts.70005","DOIUrl":"https://doi.org/10.1111/luts.70005","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aimed to evaluate the clinical efficacy and safety of silodosin in female patients with lower urinary tract symptoms (LUTSs), addressing the limited evidence supporting alpha-blocker use in this population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A 12-week, single-arm, prospective, open-label study was conducted from May 2021 to January 2023. Female patients aged over 18 with an International Prostate Symptom Score (IPSS) ≥ 8 were enrolled and treated with silodosin (8 mg once daily). Primary endpoints included changes in IPSS from baseline to 12 weeks. Secondary endpoints assessed IPSS quality of life (QOL), Overactive Bladder Symptom Score (OABSS), maximal urinary flow rate (Q max), and residual urine (RU).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Ninety-five patients were enrolled, with 85 included in the analysis. After 12 weeks, the mean total IPSS significantly decreased from 18.65 ± 6.89 at baseline to 12.54 ± 5.28 (<i>p</i> &lt; 0.001). IPSS-QOL improved from 4.14 ± 1.01 to 3.12 ± 0.79 (<i>p</i> &lt; 0.001). OABSS decreased from 6.89 ± 3.41 to 4.28 ± 2.39 (<i>p</i> &lt; 0.001), and RU reduced from 51.39 ± 55.38 to 29.95 ± 29.83 mL (<i>p</i> &lt; 0.001). Q max increased from 13.96 ± 6.74 to 16.48 ± 6.09 mL/s (<i>p</i> &lt; 0.001), while voiding volume increased from 163.02 ± 70.53 to 176.12 ± 47.16 mL (<i>p</i> = 0.026). Silodosin was well tolerated, with no serious adverse events noted.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Silodosin demonstrates efficacy and safety in treating female patients with moderate-to-severe LUTS, suggesting that it can be considered a viable treatment option alongside established therapies. Further studies are warranted to confirm these findings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143112912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the 3-Year Continuation Rate and Discontinuation Factors Between Vibegron and Mirabegron in Patients With Overactive Bladder: A Retrospective Follow-Up Study in a Rehabilitation Hospital in Japan","authors":"Shigeto Mukai,&nbsp;Masashi Nomi,&nbsp;Akihiro Yanagiuchi,&nbsp;Atsushi Sengoku","doi":"10.1111/luts.70001","DOIUrl":"10.1111/luts.70001","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The objective of this study is to compare the 3-year continuation rate and discontinuation factors between vibegron and mirabegron in patients with overactive bladder in a rehabilitation hospital in Japan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The 3-year continuation rate of the target drugs and reasons for discontinuation as well as patients' backgrounds and adverse effects were evaluated retrospectively from the medical records between September 2018 and December 2020. After selecting patients according to our inclusion and exclusion criteria, 136 cases taking mirabegron and 82 taking vibegron were adjusted for intergroup variability by propensity score matching. We performed Cox proportional hazards regression for the 3-year continuation rate and Fine-Gray proportional hazards regression for the 3-year cumulative incidence of discontinuation events. Subgroup analysis was also performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Approximately 70% of the patients analyzed had neurogenic overactive bladder. The 3-year continuation rate was 65.2% in vibegron and 30.3% in mirabegron, and the hazard ratio was 0.41 (95% confidence interval: 0.25–0.68, <i>p</i> &lt; 0.001) as for an incidence of discontinuation events of vibegron against mirabegron. The incidence of discontinuation due to inadequate efficacy was 22.7% in vibegron and 47.0% in mirabegron, and similarly the hazard ratio was 0.43 (95% confidence interval: 0.23–0.80, <i>p</i> &lt; 0.01). In the subgroup analysis, vibegron continued significantly more than mirabegron for the 3-year continuation rate in non-neurogenic overactive bladder (<i>p</i> &lt; 0.001), in spontaneous voiding (<i>p</i> &lt; 0.001), in anticholinergic combination (<i>p</i> = 0.0017), in female (<i>p</i> &lt; 0.001), and in 70 years or older (<i>p</i> = 0.0028). Additionally, a significant interaction was observed regarding the methods of emptying urine (<i>p</i> = 0.0066).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Vibegron was superior to mirabegron in the 3-year continuation rate of administration with a fewer discontinuation due to inadequate efficacy in a patient population with relatively high rates of neurogenic overactive bladder.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial Experience of Contact Laser Vaporization of the Prostate Using the New Type of Fiber for Benign Prostatic Hyperplasia in a Single Institution","authors":"Fukashi Yamamichi,&nbsp;Takaaki Inoue,&nbsp;Masaichiro Fujita,&nbsp;Koki Tominaga,&nbsp;Yousuke Yamashita,&nbsp;Masato Fujisawa","doi":"10.1111/luts.70002","DOIUrl":"10.1111/luts.70002","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The objective of this study is to evaluate our initial experience with contact laser vaporization of the prostate (CVP) using the new type of fiber for benign prostatic hyperplasia (BPH).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively evaluated 43 patients in whom CVP was performed using the new type of fiber from October 2020 to December 2021 at our institution. Total International Prostate Symptom Score (IPSS), IPSS voiding, IPSS storage, IPSS postmicturition, quality of life (QOL) index, maximum urinary flow rate (Qmax), and postvoid residual urine (PVR) were evaluated preoperatively and at 1, 3, 6, and 12 months postoperatively. Prostate volume was assessed preoperatively and at 12 months postoperatively. Complications were also evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Total IPSS, IPSS voiding, IPSS postmicturition, QOL index, and PVR showed significant improvement at 1 month postoperatively. IPSS storage showed significant improvement at 3 months postoperatively (<i>p</i> = 0.001), and Qmax showed significant improvement at 6 months postoperatively (<i>p</i> = 0.021). The preoperative prostate volume was 87.8 (65.0–116.7) ml and significantly decreased to 80.5 (42.6–97.4) ml at 12 months postoperatively (<i>p</i> = 0.002). The complications were acute prostatitis (9.3%) and temporary urinary retention (7.0%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>CVP using the new type of fiber was found to be a minimally invasive surgical procedure. There were no severe complications, and the short-term outcomes were favorable.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes of the Urothelial Barrier System in the Cyclophosphamide-Induced Cystitis in Rats by Using a Newly Established “Inside-Out” Urinary Bladder Preparation","authors":"Naoki Aizawa,&nbsp;Hiroki Natsuya,&nbsp;Tomoe Fujita","doi":"10.1111/luts.12538","DOIUrl":"10.1111/luts.12538","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The study was aimed to establish the “inside-out” preparation with the urothelium and investigate the changes in urothelial permeability of the cyclophosphamide (CYP)-induced cystitis model in rats.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In female rats with or without CYP injection, the isolated whole bladder was utilized as an “inside-out” preparation with the urothelium, which was created by reversing the bladder from a top portion. The preparation was fixed in the organ bath, and instilled with a Krebs solution (0.5 mL) through the bladder neck. After it was kept under an isovolumetric condition, high K⁺ (KCl: 50 mM) or acetylcholine (ACh: 10 μM) was added into the organ bath.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the normal bladder, the intravesical pressure of the inside-out preparation with the urothelium did not change with the addition of KCl or ACh. Contrarily, in the CYP-injected bladder 24 or 48 h after injection of CYP, the intravesical pressure of the inside-out preparation increased with the addition of KCl or ACh. Histological examinations showed a denuded and/or cracked surface of the urothelial layer, and the intensity of uroplakin III staining of the urothelial layer decreased in the CYP-injected rats.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The study demonstrated the bladder urothelium has robust barrier mechanisms for preventing the absorption of water (urine) under the normal condition. However, these barrier mechanisms were disrupted in the CYP-induced cystitis, suggesting that water and urine insults can be permeabilized into the urinary bladder, specifically to the smooth muscle layer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"16 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transient Receptor Potential Melastatin 8 Contributes to Cystitis-Induced Neuronal Sprouting and Pain Hypersensitivity Through AKT/mTOR Signaling Pathway in Interstitial Cystitis/Bladder Pain Syndrome","authors":"Liyang Wu,&nbsp;Ran Chang,&nbsp;Peng Zhang","doi":"10.1111/luts.12537","DOIUrl":"10.1111/luts.12537","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The aim of this study was to investigate the mechanism of TRPM8 in neuroproliferation and pain, as well as the relevance of the Akt/mTOR signaling pathway in mice with IC/BPS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The model of IC/BPS was established in wild and TRPM8^−/− mice. The mechanical sensitivity was measured. The number of neurite segments, length of neurites, and density of neurites were all counted. IL-6 and norepinephrine levels were detected by ELISA, Western blot was used to detect protein levels of TRPM8, Akt, p-Akt, mTOR, p-mTOR. Immunofluorescence was used to detect TRPM8 expression and distribution in neurites, neurons, and sensory nerves in mouse bladder tissue.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Pain threshold in the IC/BPS group was decreased, and neurite segments, length, and density were all significantly enhanced when compared to the control group. The parameters in the IC/BPS model + Menthol group were more statistically significant. Neurite number and density were lower in TRPM8 knockout-model mice than in IC/BPS model mice. The expression of TRPM8 and the ratios of p-Akt/Akt and p-mTOR/mTOR rose in the IC/BPS model group. In TRPM8 knockout-model mice, the ratios of p-Akt/Akt and p-mTOR/mTOR were not substantially different from those in the control group. TRPM8 knockout-model mice had considerably lower levels of serum IL-6 and urine norepinephrine than IC/BPS model mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>TRPM8 can induce pain hypersensitivity and sensory nerve proliferation by activating Akt/mTOR pathway and raising the expression of IL-6 and norepinephrine in IC/BPS models. These findings offer new perspectives on IC/BPS treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"16 6","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}